Metastatic Melanoma clinical trials

Explore recruiting metastatic melanoma clinical trials.

Recruiting metastatic melanoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma

Germany, Lithuania, Spain, Estonia, Italy, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors

Spain, Germany, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab vs Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma

Romania, Finland, Austria, Italy, Germany, Belgium +7 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D

Hungary, Poland, Greece, Spain, Italy, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

CRISPR-TIL for metastatic melanoma

Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

CRISPR-TIL for metastatic melanoma

Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Metastatic Melanoma trials by city

Metastatic Melanoma in Toronto Metastatic Melanoma in Vancouver Metastatic Melanoma in Montreal Metastatic Melanoma in Calgary Metastatic Melanoma in Edmonton Metastatic Melanoma in Ottawa Metastatic Melanoma in Winnipeg Metastatic Melanoma in Quebec City Metastatic Melanoma in Hamilton Metastatic Melanoma in Kitchener Metastatic Melanoma in London Metastatic Melanoma in Halifax Metastatic Melanoma in New York Metastatic Melanoma in Los Angeles Metastatic Melanoma in Chicago Metastatic Melanoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease